期刊文献+

抗血管生成靶向药物相关性高血压 被引量:3

Hypertension Developed by the Anti-angiogenesis Target Drug
暂未订购
导出
摘要 高血压是抗血管生成靶向药物最常见的副作用之一,其机制和管理受到重视。本文就靶向药物导致高血压的机制进行了探讨,考虑可能与抗血管生成药物的作用靶点有关,即影响了血管内皮生长因子的功能所致;介绍临床如何进行高血压管理并建议在抗血管生成靶向药物使用过程中规范地监测、控制血压,开展相关研究。 Hypertension, one of the most common side-effect developed by the anti--angiogenesis target drug, is paid more attention on the hypertension mechanism and management. The hypertension is possibly relhted to influence on VEGF's physiological function and some hypertension management suggestions are addressed .
作者 张弦 张阳
出处 《医学与哲学(B)》 2010年第10期37-38,共2页 Medicine & Philosophy(B)
关键词 抗血管生成靶向药物 副作用 高血压机制 高血压管理 anti-- angiogenesis target drug, side effect, hypertension mechanism, hypertension management
  • 相关文献

参考文献14

  • 1Ranpura V, Pulipati B, Chu D. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis [J]. Am J Hypertens. 2010,23(5):460-468.
  • 2Wu S, Chen J J, Kudelka A. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis[J]. Lancet Oncol,2008,9(2):117-123.
  • 3Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review andmeta-analysis[J]. Acta Oncol,2009,48(1):9-17.
  • 4Azizi M, Chedid A,Oudard S. Home blood pressure monitoring in patients receiving sunitinib[J]. N Engl J Med, 2008,358 : 95 - 97.
  • 5anahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis[J]. Cell, 1996, 86 : 353- 364.
  • 6Inai T, Mancuso M, Hashizume H. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts[J]. Am J Pathol,2004, 165:35-52.
  • 7Kamba T, Tam B Y, Hashizume H. VEGF--dependent plasticity of fenestrated capillaries in the normal adult microvasculature[J]. Am J Physiol Heart Circ Physiol,2006, 290(2):H509-511.
  • 8Kamba T, McDonald D M. Mechanisms of adverse effects of anti- VEGF therapy for cancer[J]. Br J Cancer, 2007,96:1788-1795.
  • 9Mourad J J, des Guetz G, Debbabi H. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation[J]. Ann Oncol,2008, 19:927-934.
  • 10Steeghs N, Gelderblom H, Roodt J O. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor[J]. Clin Cancer Res, 2008, 14 : 3470-3476.

同被引文献26

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部